Clinical trial
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome
NCT03473223 is registered in ClinicalTrials.gov with CSL Behring as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome
- Lead sponsor
- CSL Behring
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 21, 2018
- Completion date
- November 17, 2023
- Enrollment
- 18,226 (actual)
- Sites
- 903
Conditions
As the registry lists them; a condition with its own page is linked.